About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Georgia | 476 Studies

Clinical Trials LymphomaGeorgia

Lymphoma Clinical Trials in Georgia

Find 476 clinical trials for lymphoma near Georgia. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Georgia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 61-80 of 476 trials

CompletedStudy of the Glutaminase Inhibitor CB-839 in Hematological TumorsMany tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.NCT02071888·Scottsdale, Arizona and 6 others CompletedLMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaRATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells.NCT00085150·Atlanta, Georgia and 4 others

PreviousPage 4 of 24Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedDenintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaThis is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with…NCT02855359·Birmingham, Alabama and 34 others

CompletedStudy of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaThis phase I clinical trial studies the side effects and the best dose of phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in treating…NCT02049541·Atlanta, Georgia and 1 other

CompletedStudy of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaThe purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or…NCT00312845·Opelika, Alabama and 205 others

CompletedAMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/AttemptsThis study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral…NCT00396331·Duarte, California and 7 others

CompletedTotal-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerRATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells.NCT00044954·Denver, Colorado and 13 others

Active not recruitingA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLThis study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated…NCT02972840·Tucson, Arizona and 227 others

CompletedVELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaThe purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell…NCT00085696·Los Angeles, California and 12 others

CompletedSafety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaTo characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.NCT03770000·Los Angeles, California and 14 others

Active not recruitingValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including…NCT04703192·Duarte, California and 59 others

CompletedClinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor…NCT03904134·Duarte, California and 51 others

RecruitingSynKIR-310 for Relapsed/Refractory B-NHLThis first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants…NCT06544265·Denver, Colorado and 4 others

CompletedComparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00059839·Birmingham, Alabama and 158 others

CompletedStudy of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL).NCT02669017·La Jolla, California and 10 others

CompletedPhase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.NCT01504776·Augusta, Georgia

TerminatedA Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell LymphomaThis is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of…NCT05972720·Little Rock, Arkansas and 30 others

TerminatedAn Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesThis is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies.NCT01929941·Atlanta, Georgia and 2 others

CompletedVemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600…NCT03220035·Birmingham, Alabama and 115 others

CompletedDose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesA two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination…NCT03397706·Los Angeles, California and 27 others

Other Conditions in Georgia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia